While clearly an attractive treatment for patients with familial hypercholesterolemia who have mutations of the PCSK9 gene and are difficult to treat with statins, the potential of these agents lies in treatment of the larger population of dyslipidemic patients. Here, PCSK9 is linked to familial hypercholesterolemia.